GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 444,000 kg CO2e for Scope 2 (market-based), resulting in a combined total of about 565,000,000 kg CO2e for both scopes. In the UK, GSK's Scope 1 and 2 emissions were reported at approximately 92,000 kg CO2e. GSK has set ambitious climate commitments, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030. They achieved a 15% reduction in Scope 1 and 2 emissions from 2020 to 2021. Looking ahead, GSK targets an 80% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, with a long-term goal of a 90% reduction by 2045, both from a 2020 baseline. For Scope 3 emissions, GSK is committed to an 80% reduction by 2030 and a 90% reduction by 2045, encompassing categories such as purchased goods and services, business travel, and waste generated in operations. GSK's overarching goal is to achieve net zero greenhouse gas emissions across its full value chain by 2045, with all residual emissions to be neutralised. These commitments align with GSK's participation in the Science Based Targets initiative (SBTi), reinforcing their dedication to climate action within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 430,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000 | 00,000 | 000,000 |
Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000 | 0,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.